These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 16878999)

  • 21. Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine.
    Derosa G; Mereu R; Salvadeo SA; D'Angelo A; Ciccarelli L; Piccinni MN; Ferrari I; Gravina A; Maffioli P; Cicero AF
    Intern Med; 2009; 48(5):265-71. PubMed ID: 19252346
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel pharmacologic agents for type 2 diabetes.
    Uwaifo GI; Ratner RE
    Endocrinol Metab Clin North Am; 2005 Mar; 34(1):155-97. PubMed ID: 15752927
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Options for combination therapy in type 2 diabetes: comparison of the ADA/EASD position statement and AACE/ACE algorithm.
    Bailey T
    Am J Med; 2013 Sep; 126(9 Suppl 1):S10-20. PubMed ID: 23953074
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects.
    Virtanen KA; Hällsten K; Parkkola R; Janatuinen T; Lönnqvist F; Viljanen T; Rönnemaa T; Knuuti J; Huupponen R; Lönnroth P; Nuutila P
    Diabetes; 2003 Feb; 52(2):283-90. PubMed ID: 12540598
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The use of insulin secretagogues in the treatment of type 2 diabetes.
    Luna B; Hughes AT; Feinglos MN
    Prim Care; 1999 Dec; 26(4):895-915. PubMed ID: 10523467
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metformin and pioglitazone: Effectively treating insulin resistance.
    Staels B
    Curr Med Res Opin; 2006; 22 Suppl 2():S27-37. PubMed ID: 16914073
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complementing insulin therapy to achieve glycemic control.
    Barnett AH
    Adv Ther; 2013 Jun; 30(6):557-76. PubMed ID: 23797471
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Pro12Ala variant at the peroxisome proliferator-activated receptor gamma gene and change in obesity-related traits in the Diabetes Prevention Program.
    Franks PW; Jablonski KA; Delahanty L; Hanson RL; Kahn SE; Altshuler D; Knowler WC; Florez JC;
    Diabetologia; 2007 Dec; 50(12):2451-60. PubMed ID: 17898990
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes.
    Després JP
    Diabetes Metab; 2003 Sep; 29(4 Pt 2):6S53-61. PubMed ID: 14502101
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes.
    Freemark M; Bursey D
    Pediatrics; 2001 Apr; 107(4):E55. PubMed ID: 11335776
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent diabetes issues affecting the primary care clinician.
    Sando KR; Barboza J; Willis C; Taylor J
    South Med J; 2011 Jun; 104(6):456-61. PubMed ID: 21886036
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting type 2 diabetes.
    Schwanstecher C; Schwanstecher M
    Handb Exp Pharmacol; 2011; (203):1-33. PubMed ID: 21484565
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Harnessing the weight-regulating properties of glucagon-like peptide-1 in the treatment of type 2 diabetes.
    Sesti G
    Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():4-10. PubMed ID: 19878256
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacologic prevention or delay of type 2 diabetes mellitus.
    Anderson DC
    Ann Pharmacother; 2005 Jan; 39(1):102-9. PubMed ID: 15562143
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy.
    Setter SM; Iltz JL; Thams J; Campbell RK
    Clin Ther; 2003 Dec; 25(12):2991-3026. PubMed ID: 14749143
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity.
    Gokcel A; Gumurdulu Y; Karakose H; Melek Ertorer E; Tanaci N; BascilTutuncu N; Guvener N
    Diabetes Obes Metab; 2002 Jan; 4(1):49-55. PubMed ID: 11874442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Insulin resistance syndrome: options for treatment.
    Granberry MC; Fonseca VA
    South Med J; 1999 Jan; 92(1):2-15. PubMed ID: 9932820
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The management of type 2 diabetes in children and adolescents.
    Daaboul JJ; Siverstein JH
    Minerva Pediatr; 2004 Jun; 56(3):255-64. PubMed ID: 15252375
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What are the pharmacotherapy options for treating prediabetes?
    Daniele G; Abdul-Ghani M; DeFronzo RA
    Expert Opin Pharmacother; 2014 Oct; 15(14):2003-18. PubMed ID: 25139488
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
    Halimi S
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.